SGLT2 inhibitor
SGLT2 inhibitors, also called gliflozins, are a class of medications that alter essential physiology of the nephron; unlike SGLT1 inhibitors that modulate sodium/glucose channels in the intestinal mucosa. The foremost metabolic effect appears to show that this pharmaceutical class inhibits reabsorption of glucose in the kidney and therefore lower blood sugar. They act by inhibiting sodium-glucose transport protein 2 (SGLT2). SGLT2 inhibitors are used in the treatment of type II diabetes mellitus (T2DM). Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in T2DM patients. Several medications of this class have been approved or are currently under development. In studies on canagliflozin, a member of this class, the medication was found t
ATC code A10COVID-19 drug developmentCanagliflozinCanagliflozin/metforminDapagliflozinDapagliflozin/metforminDapagliflozin/saxagliptinDapagliflozin/saxagliptin/metforminDiabetesDiabetes medicationDiabetic ketoacidosisDiabetic nephropathyDiscovery and development of gliflozinsEmpagliflozinEmpagliflozin/linagliptinEmpagliflozin/linagliptin/metforminEmpagliflozin/metforminErtugliflozinFournier gangreneGliflozinGliflozinsGlucagon-like peptide-1 receptor agonistIpragliflozinKetoacidosisKetosisLuseogliflozinPDE5 inhibitorRemogliflozin etabonateRenal glucose reabsorptionSGLT-2 inhibitorSGLT2 inhibitorsSodium-glucose cotransporter-2 inhibitorsSodium/glucose cotransporter 2Sodium glucose transporter (SGLT2) inhibitorsSotagliflozinTofogliflozinType 2 diabetes
Link from a Wikipage to another Wikipage
primaryTopic
SGLT2 inhibitor
SGLT2 inhibitors, also called gliflozins, are a class of medications that alter essential physiology of the nephron; unlike SGLT1 inhibitors that modulate sodium/glucose channels in the intestinal mucosa. The foremost metabolic effect appears to show that this pharmaceutical class inhibits reabsorption of glucose in the kidney and therefore lower blood sugar. They act by inhibiting sodium-glucose transport protein 2 (SGLT2). SGLT2 inhibitors are used in the treatment of type II diabetes mellitus (T2DM). Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in T2DM patients. Several medications of this class have been approved or are currently under development. In studies on canagliflozin, a member of this class, the medication was found t
has abstract
SGLT2 inhibitors, also called ...... and diastolic blood pressure.
@en
Link from a Wikipage to an external page
Wikipage page ID
46,745,950
page length (characters) of wiki page
Wikipage revision ID
1,023,418,726
Link from a Wikipage to another Wikipage
wikiPageUsesTemplate
comment
SGLT2 inhibitors, also called ...... ss, the medication was found t
@en
label
SGLT2 inhibitor
@en